Adaptive Biotech director gifts 12,539 shares

Adaptive Biotechnologies Corp (ADPT) director Katey Einterz Owen reported a bona fide gift of 12,539 shares of common stock on August 31, 2026.

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp (ADPT) director Katey Einterz Owen reported a bona fide gift of 12,539 shares of common stock on August 31, 2026. The transaction was a disposition by gift, not a sale for value, and Owen now holds 66,100 shares of Adaptive Biotechnologies common stock directly.

Insider Trade Summary

12,539 shares gifted

Gift 1 txn

Insider OWEN KATEY EINTERZ

Role Director

Type	Security	Shares	Price	Value
Gift	Common Stock F1	12,539	--	--

Holdings After Transaction: Common Stock — 66,100 shares (Direct)

Footnotes (1)

1. F1. Price is not applicable to dispositions resulting from bona fide gifts.

Key Figures

Shares gifted: 12,539 shares Shares held after transaction: 66,100 shares Gift transactions count: 1 transaction +1 more

4 metrics

Shares gifted 12,539 shares Bona fide gift of common stock on August 31, 2026

Shares held after transaction 66,100 shares Direct holdings of common stock following the reported gift

Gift transactions count 1 transaction Number of bona fide gift transactions reported in this Form 4

Gift shares total 12,539 shares Total shares reported as bona fide gifts in this Form 4

Key Terms

bona fide gift, Rule 10b5-1, Form 4, non-derivative

4 terms

bona fide gift regulatory

"The transaction is reported with code G, described as a bona fide gift"

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

Rule 10b5-1 regulatory

"The Rule 10b5-1 checkbox is not marked for this transaction"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Form 4 regulatory

"Post-transaction holdings are stated in the Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

"The gift involves a non-derivative holding of common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ADPT director Katey Einterz Owen report?

Katey Einterz Owen reported a bona fide gift of Adaptive Biotechnologies common stock on August 31, 2026, transferring shares as a gift rather than selling them for cash consideration.

How many ADPT shares were transferred in the reported gift?

The filing reports that 12,539 shares of Adaptive Biotechnologies common stock were transferred as a bona fide gift. A footnote states that price is not applicable to dispositions resulting from bona fide gifts.

How many Adaptive Biotechnologies (ADPT) shares does the director hold after the transaction?

After the reported gift, Katey Einterz Owen directly holds 66,100 shares of Adaptive Biotechnologies common stock, as stated in the post-transaction holdings line of the Form 4.

Was the ADPT insider transaction made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates that the Rule 10b5-1 checkbox is not marked, so the reported bona fide gift of 12,539 shares was not affirmatively reported as being made under a Rule 10b5-1 trading plan.

What type of code is used for the ADPT insider transaction?

The transaction is reported with code G, which the form describes as a bona fide gift. This indicates a charitable or other gift disposition of shares rather than an open-market purchase or sale.

Does the Form 4 for ADPT disclose any option exercises or derivative transactions?

No. The Form 4 summary shows no derivative transactions and no option exercises; it reports only one non-derivative transaction, the bona fide gift of 12,539 common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 07:12 PM EDT Accepted by SEC EDGAR 09/02/2026 - 07:12 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OWEN KATEY EINTERZ

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WASHINGTON 98109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		G		12,539	D	(1)	66,100	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Price is not applicable to dispositions resulting from bona fide gifts.

	/s/ Katey Einterz Owen by Kyle Piskel, Attorney-in-Fact	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)